Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointesitnal Malignancies
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- 01 Feb 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2017 as per ClinicalTrials.gov record.
- 18 Nov 2015 Status changed from active, no longer recruiting to completed, as published in the Investigational New Drugs.
- 18 Nov 2015 Results published in the Investigational New Drugs